Genome-wide association study of prostate cancer-specific survival

Robert Szulkin, Robert Karlsson, Thomas Whitington, Markus Aly, Henrik Gronberg, Rosalind A Eeles, Douglas F Easton, Zsofia Kote-Jarai, Ali Amin Al Olama, Sara Benlloch, Kenneth Muir, Graham G Giles, Melissa C Southey, Liesel M FitzGerald, Brian E Henderson, Fredrick R Schumacher, Christopher A Haiman, Csilla Sipeky, Teuvo L J Tammela, Børge G NordestgaardTimothy J Key, Ruth C Travis, David E Neal, Jenny L Donovan, Freddie C Hamdy, Paul D P Pharoah, Nora Pashayan, Kay-Tee Khaw, Janet L Stanford, Stephen N Thibodeau, Shannon K McDonnell, Daniel J Schaid, Christiane Maier, Walther Vogel, Manuel Luedeke, Kathleen Herkommer, Adam S Kibel, Cezary Cybulski, Jan Lubiński, Wojciech Kluźniak, Lisa Cannon-Albright, Hermann Brenner, Volker Herrmann, Bernd Holleczek, Jong Y Park, Thomas A Sellers, Hui-Yi Lim, Chavdar Slavov, Radka P Kaneva, Vanio I Mitev, PRACTICAL consortium

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

27 Citationer (Scopus)

Abstract

BACKGROUND: Unnecessary intervention and overtreatment of indolent disease are common challenges in clinical management of prostate cancer. Improved tools to distinguish lethal from indolent disease are critical.

METHODS: We performed a genome-wide survival analysis of cause-specific death in 24,023 prostate cancer patients (3,513 disease-specific deaths) from the PRACTICAL and BPC3 consortia. Top findings were assessed for replication in a Norwegian cohort (CONOR).

RESULTS: We observed no significant association between genetic variants and prostate cancer survival.

CONCLUSIONS: Common genetic variants with large impact on prostate cancer survival were not observed in this study.

IMPACT: Future studies should be designed for identification of rare variants with large effect sizes or common variants with small effect sizes.

Citationsformater